Industry Briefs: Apr. 23, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
3M Drug Delivery Systems has expanded its pressurized metered dose inhaler fill line at its facility in Northridge, California. Read More
Baxter International will invest $1 billion over the next five years for a new manufacturing facility in Georgia for plasma-derived therapies. Read More
Eisai has amended its license agreement with Teikoku Pharma USA for the Aricept transdermal patch system. Read More
Kemwell Biopharma has expanded its pharmaceutical development laboratories, including a 7500-ft2 cGMP pilot facility, in Bangalore, India, to support pharmaceutical projects from preformulation to finished products.
Merck Millipore, the life-science division of Merck KGaA, has announced the schedule for the Merck Millipore Live Lab Tour 2012 that will visit nine science parks and institutions in Europe during May–June 2012. Click here for the schedule and more details.
Mylan is expanding its operations in Dublin and Galway, Ireland. Read More
Patheon has formed Patheon Certified Consultants, a new consulting services comprised of industry professionals to assist emerging biotechnology and pharmaceutical companies. Read More
West Pharmaceutical Services has dedicated new cleanroom manufacturing capabilities at its Scottsdale, Arizona, pharmaceutical delivery systems engineering center. West will manufacture its Daikyo Crystal Zenith 1-mL long prefillable syringe system at the Scottsdale facility.
People News
AMRI has appointed Christopher Conway and Louis Garguilo as vice-president in its business-development units. Read More
Novasep has appointed Jean-Claude Romain as corporate quality director and Alain Lamproye as director of the company’s bioproduction sites in Belgium. Read More
Quintiles has named Tom Pike as CEO. Read More
Is “right first time, every time” a pipedream for metabolite identification by LC-MS?
March 18th 2025The dream state If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery. At SCIEX, we believe that metabolite identification using the ZenoTOF 7600 system gets close to this dream state.
